Hsp90: a drug target?

Area of Science:

• Molecular Biology
• Cellular Stress Response
• Cancer Therapeutics

Background:

• Heat shock protein 90 (Hsp90) is a crucial molecular chaperone.
• Hsp90 stabilizes client proteins, offering cellular protection against stressors like cancer.
• Dysregulation of Hsp90 is common in cancer cells, suggesting therapeutic potential.

Purpose of the Study:

• To explore the role of Hsp90 in cellular protection and cancer.
• To review the development and clinical relevance of Hsp90 inhibitors.
• To highlight novel C-terminal Hsp90 inhibitors.

Main Methods:

• Review of existing literature on Hsp90 function and inhibition.
• Analysis of clinical trial data for Hsp90 inhibitors.
• In vitro studies of newly developed C-terminal Hsp90 inhibitors.

Main Results:

• N-terminal Hsp90 inhibitors (e.g., geldanamycin analogues) have undergone clinical trials.
• Hsp90 overexpression or hyperactivity is observed in cancer cells, indicating selectivity for inhibitors.
• Emerging C-terminal Hsp90 inhibitors demonstrate promising in vitro anti-cancer activity.

Conclusions:

• Hsp90 is a viable therapeutic target in oncology.
• Development of Hsp90 inhibitors has progressed from early analogues to more clinically applicable compounds.
• C-terminal Hsp90 inhibition represents a promising new strategy for cancer treatment.